Business Wire

Hurricane Electric Expands Global Network to The Albanian Internet Exchange 

24.5.2022 12:20:00 EEST | Business Wire | Press release

Share

Hurricane Electric, the world’s largest IPv6-native Internet backbone announced today that it has further expanded its presence in Southeastern Europe by connecting to the Albanian Neutral Internet eXchange (ANIX).

ANIX is the first neutral and not-for-profit Internet Exchange point in Albania and is hosted and managed by Namex in the carrier-grade data center of RASH, the Albanian Academic Network, in Tirana. ANIX went live in March 2018. Prior to the establishment of ANIX, traffic between Albanian endpoints had to pass through foreign countries. ISPs throughout Albania and the world come to ANIX to interconnect their networks.

Hurricane Electric’s presence in ANIX will provide reduced latency and improved fault tolerance, load balancing and congestion management infrastructure. The added direct connectivity paths also increase the reach of Hurricane Electric’s next-generation (IPv6) Internet infrastructure and services. Additionally, ANIX members can now exchange IP traffic, or “peer,” with Hurricane Electric’s rich global Internet backbone.

Namex is an Internet Exchange Point based in Rome, Italy, established in 1995. Namex and RASH, the Albanian Academic Network, established in 2007, have been conducting the ANIX pro-bono effort to improve the connectivity of Albanian ISPs to each other and to the global Internet. ANIX features state-of-the-art devices, installed in the RASH data center which is equipped with numerous features to ensure uptime, including N + 1 UPS, temperature and humidity sensors, and real-time monitoring of the facility’s critical infrastructure.

In addition to providing increased network capacity through 100GE (100 Gigabit Ethernet), 10GE (10 Gigabit Ethernet) and GigE (1 Gigabit Ethernet) ports, Hurricane Electric’s vast global network, offers over 20,000 BGP sessions with over 9,000 different networks via more than 250 major exchange points and thousands of customers and private peering ports.

“Hurricane Electric’s is excited to connect to ANIX while expanding our footprint in Southeastern Europe," said Mike Leber, President of Hurricane Electric. “The new connection will enable local ISPs and other networks to take advantage of Hurricane Electric’s rich global network, while helping to strengthen Albania’s Internet connectivity.”

About Hurricane Electric

Hurricane Electric operates its own global IPv4 and IPv6 network and is considered the largest IPv6 backbone in the world. Within its global network, Hurricane Electric is connected to over 250 major exchange points and exchanges traffic directly with more than 9,000 different networks. Employing a resilient fiber-optic topology, Hurricane Electric has no less than five redundant 100G paths crossing North America, four separate 100G paths between the U.S. and Europe, and 100G rings in Europe and Asia. Hurricane also has a ring around Africa and a ring through Australia and New Zealand. Hurricane Electric offers IPv4 and IPv6 transit solutions over the same connection. Connection speeds available include 100GE (100 gigabits/second), 10GE, and gigabit ethernet. Additional information can be found at http://he.net.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Adam Waitkunas
Milldam Public Relations
adam.waitkunas@milldampr.com
(978) 828-8304

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye